Management of elderly patients with gliomas

Oncologist

Volumn 19, Issue 12, 2014, Pages 1258-1267

  Pérez Larraya, Jaime Gállego ^a   Delattre, Jean Yves ^b,c,d  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CNRS   (France)

Author keywords

Elderly; Glioblastoma; Glioma; High grade glioma; Low grade glioma; Old patients

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT CHEMORADIOTHERAPY; AGING; ANAPLASTIC GLIOMA; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COGNITION; GLIOBLASTOMA; GLIOMA; HUMAN; INCIDENCE; KARNOFSKY PERFORMANCE STATUS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGED; BRAIN NEOPLASMS; COMPLICATION; DISEASE COURSE; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; DISEASE PROGRESSION; GLIOMA; HUMANS; PROGNOSIS; QUALITY OF LIFE;

EID: 84919327006     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0170     Document Type: Article

References (97)

1. Delafuente JC.The silver tsunami is coming: Will pharmacy be swept away with the tide? Am J Pharm Educ 2009;73:1.
2. Bartels SJ, Naslund JA. The underside of the silver tsunami: Older adults and mental health care. N Engl J Med 2013;368:493–496.
3. Institute of Medicine. Delivering High Quality Cancer Care: Charting a New Course for a System in Crisis. Washington, D.C.: National Academies Press, 2013.
4. Ostrom QT, Gittleman H, Farah P et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 2013;15(Supplement 2):ii1–ii56.
5. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977–2000. Cancer 2004;101:2293–2299.
6. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985–1999. Neuro Oncol 2006;8:27–37.
7. Chakrabarti I, Cockburn M, Cozen W et al. A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer 2005;104:2798–2806.
8. Elia-Pasquet S, Provost D, Jaffré A et al. Incidence of central nervous system tumors in Gironde, France. Neuroepidemiology 2004;23:110–117.
9. Balducci L, Colloca G, Cesari M et al. Assessment and treatment of elderly patients with cancer. Surg Oncol 2010;19:117–123.
10. Fried LP, Hall WJ. Editorial: Leading on behalf of an aging society. J Am Geriatr Soc 2008;56: 1791–1795.
11. Laperriere N, Weller M, Stupp R et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 2013;39:350–357.
12. Li J, Wang M, Won M et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 2011; 81:623–630.
13. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061–2067.
14. Gross CP, Herrin J, Wong N et al. Enrolling older persons in cancer trials: The effect of sociodemo-graphic, protocol, andrecruitment centercharacteristics. J Clin Oncol 2005;23:4755–4763.
15. Yee KW, Pater JL, Pho L et al. Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? J Clin Oncol 2003;21:1618–1623.
16. Barnholtz-Sloan JS, Williams VL, Maldonado JL et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 2008;108:642–648.
17. Scott J, Tsai YY, Chinnaiyan P et al. Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2011;81:206–210.
18. Kita D, Ciernik IF, Vaccarella S et al. Age as a predictive factor in glioblastomas: Population-based study. Neuroepidemiology 2009;33:17–22.
19. Gulati S, Jakola AS, Johannesen TB et al. Survival and treatment patterns of glioblastoma in the elderly: A population-based study. World Neurosurg 2012;78:518–526.
20. Aapro MS, Köhne CH, Cohen HJ et al. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. The Oncologist 2005;10: 198–204.
21. Gállego Pérez-Larraya J, Delattre JY. Treating glioblastoma in the elderly. CNS Oncol 2012;1: 193–201.
22. Pruitt AA. Medical management of patients with brain tumors. Curr Treat Options Neurol 2011; 13:413–426.
23. Ricard D, Idbaih A, Ducray F et al. Primary brain tumours in adults. Lancet 2012;379:1984–1996.
24. Tatsuno I, Sugiyama T, Suzuki S et al. Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab 2009;94:1671–1677.
25. Chevalet P, Masseau-Imbert A, Durand-Fix MH et al. [Giant cell arteritis after the age of 75]. Ann Med Interne (Paris) 2002;153:373–377.
26. Drappatz J, Schiff D, Kesari S et al. Medical management of brain tumor patients. Neurol Clin 2007;25:1035–1071, ix.
27. Vélez L, Selwa LM. Seizure disorders in the elderly. Am Fam Physician 2003;67:325–332.
28. Waterhouse E, Towne A. Seizures in the elderly: Nuances in presentation and treatment. Cleve Clin J Med 2005;72(Supplement 3):S26–S37.
29. Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886–1893.
30. Arif H, Buchsbaum R, Pierro J et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol 2010;67:408–415.
31. Zeber JE, Copeland LA, Pugh MJ. Variation in antiepileptic drug adherence among older patients with new-onset epilepsy. Ann Pharmacother 2010; 44:1896–1904.
32. Contin M, Mohamed S, Albani F et al. Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. Epilepsy Res 2012;98: 130–134.
33. Gehring K, Patwardhan SY, Collins R et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol 2012;107:165–174.
34. Minton O, Richardson A, Sharpe M et al. Psychostimulants for the management of cancer-related fatigue: A systematic review and meta-analysis. J Pain Symptom Manage 2011;41:761–767.
35. Yennurajalingam S, Palmer JL, Chacko R et al. Factors associated with response to methylphenidate in advanced cancer patients. The Oncologist 2011;16:246–253.
36. Berger A. Treating fatigue in cancer patients. The Oncologist 2003;8(Supplement 1):10–14.
37. Kaloshi G, Psimaras D, Mokhtari K et al. Supratentorial low-grade gliomas in older patients. Neurology 2009;73:2093–2098.
38. Wrensch M, Rice T, Miike R et al. Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol 2006;8:12–26.
39. Iwamoto FM, Reiner AS, Nayak L et al. Prognosis and patterns of care in elderly patients with glioma. Cancer 2009;115:5534–5540.
40. Pouratian N, Mut M, Jagannathan J et al. Low-grade gliomas in older patients: A retrospective analysis of prognostic factors. J Neurooncol 2008; 90:341–350.
41. Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: Long-term follow-up from Mayo Clinic. Cancer 2009;115:3969–3978.
42. Pignatti F, van den Bent M, Curran D et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20: 2076–2084.
43. Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996;36:549–556.
44. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356:1527–1535.
45. Wick W, Platten M, Meisner C et al. Temozo-lomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707–715.
46. Tanaka S, Meyer FB, Buckner JC et al. Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. J Neurooncol 2012;110:227–235.
47. van den Bent MJ, Brandes AA, Taphoorn MJ et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344–350.
48. Ducray F, del Rio MS, Carpentier C et al. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocy-toma. J Neurooncol 2011;101:457–462.
49. Lowry JK, Snyder JJ, Lowry PW. Brain tumors in the elderly: Recent trends in a Minnesota cohort study. Arch Neurol 1998;55:922–928.
50. Laigle-Donadey F, Sanson M. [Pattern of care of high-grade gliomas]. Rev Prat 2006;56:1779–1786.
51. Marijnen CA, van den Berg SM, van Duinen SG et al. Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: A retrospective single institution analysis. Radiother Oncol 2005;75:210–216.
52. Chaichana KL, Garzon-Muvdi T, Parker S et al. Supratentorial glioblastoma multiforme: The role of surgical resection versus biopsy among older patients. Ann Surg Oncol 2011;18:239–245.
53. Oszvald A, Güresir E, Setzer M et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 2012;116:357–364.
54. Ewelt C, Goeppert M, Rapp M et al. Glioblastoma multiforme of the elderly: The prognostic effect of resection on survival. J Neurooncol 2011; 103:611–618.
55. Kelly PJ, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 1994;34:62–66; discussion 66–67.
56. Pierga JY, Hoang-Xuan K, Feuvret L et al. Treatment of malignant gliomas in the elderly. J Neurooncol 1999;43:187–193.
57. Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme: Preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114:587–594.
58. Vuorinen V, Hinkka S, Färkkilä M et al. Debulking or biopsy of malignant glioma in elderly people: A randomised study. Acta Neurochir (Wien) 2003; 145:5–10.
59. Iwamoto FM, Cooper AR, Reiner AS et al. Glioblastoma in the elderly: The Memorial Sloan-Kettering Cancer Center Experience (1997–2007). Cancer 2009;115:3758–3766.
60. Idbaih A, Taillibert S, Simon JM et al. Short course of radiation therapy in elderly patients with glioblastoma multiforme. Cancer Radiother 2008; 12:788–792.
61. Hoegler DB, Davey P. A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol 1997;33:201–204.
62. Hingorani M, Colley WP, Dixit S et al. Hypo-fractionated radiotherapy for glioblastoma: Strategy for poor-risk patients or hope for the future? Br J Radiol 2012;85:e770–e781.
63. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22: 1583–1588.
64. Laigle-Donadey F, Figarella-Branger D, Chinot O et al. Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol 2010;99:89–94.
65. Chinot OL, Barrie M, Frauger E et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004;100:2208–2214.
66. Glantz M, Chamberlain M, Liu Q et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003;97:2262–2266.
67. Malmström A, Grønberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916–926.
68. Holdhoff M, Rosner GL, Alcorn S et al. ‘Elderly’ patients with newly diagnosed glioblastoma deserve optimal care. J Neurooncol 2013;113:343–344.
69. Ducray F, Benouaich-Amiel A, Idbaih A et al. Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status. J Neurooncol 2008;88:185–188.
70. Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial. J Clin Oncol 2011; 29:3050–3055.
71. Reyes-Botero G, Honnorat J, Chinot O et al. Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial. J Clin Oncol 2013;31(Supplement):2020.
72. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352: 987–996.
73. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459–466.
74. Combs SE, Wagner J, Bischof M et al. Post-operative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 2008; 70:987–992.
75. Sijben AE, McIntyre JB, Roldán GB et al.Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 2008;89:97–103.
76. Minniti G, De Sanctis V, Muni R et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008;88:97–103.
77. Minniti G, Armosini V, Salvati M et al. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 2011;103:683–691.
78. Brandes AA, Franceschi E, Tosoni A et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: Correlation with MGMT promoter methylation status. Cancer 2009;115:3512–3518.
79. Barker CA, Chang M, Chou JF et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol 2012;109:391–397.
80. Gerstein J, Franz K, Steinbach JP et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 2010;97:382–386.
81. Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: A meta-analysis. PLoS One 2013;8:e74242.
82. Fiorentino A, Caivano R, Chiumento C et al. Comorbidity assessment and adjuvant radiochemo-therapy in elderly affected by glioblastoma. Med Oncol 2012;29:3467–3471.
83. Minniti G, Lanzetta G, Scaringi C et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2012; 83:93–99.
84. Minniti G, Scaringi C, Baldoni A et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int J Radiat Oncol Biol Phys 2013;86: 285–291.
85. Lutterbach J, Bartelt S, Momm F et al. Is older age associated with a worse prognosis due to different patterns of care?A long-termstudyof 1346 patients with glioblastomas or brain metastases. Cancer 2005;103:1234–1244.
86. Wiestler B, Claus R, Hartlieb SA et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: An analysis of the NOA-08 study collective. Neuro Oncol 2013;15:1017–1026.
87. Batchelor TT, Betensky RA, Esposito JM et al. Age-dependent prognostic effects of genetic alter-ations in glioblastoma. Clin Cancer Res 2004;10: 228–233.
88. Simmons ML, Lamborn KR, Takahashi M et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001;61:1122– 1128.
89. Kleinschmidt-DeMasters BK, Lillehei KO, Var-ella-Garcia M. Glioblastomas in the older old. Arch Pathol Lab Med 2005;129:624–631.
90. Larbi A, Franceschi C, Mazzatti D et al. Aging of theimmune systemas aprognosticfactor for human longevity. Physiology (Bethesda) 2008;23:64–74.
91. Yin AA, Zhang LH, Cheng JX et al. The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: A meta-analysis. PLoS One 2014;9:e85102.
92. Gerstner ER, Yip S, Wang DL et al. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009;73:1509–1510.
93. Reifenberger G, Hentschel B, Felsberg J et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012.
94. Minniti G, Salvati M, Arcella A et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 2011; 102:311–316.
95. Holdhoff M, Chamberlain MC. Controversiesin the treatment of elderly patients with newly diagnosed glioblastoma. J Natl Compr Canc Netw 2013;11:1165–1172;quiz 1173.
96. Chamberlain MC. Treatment of newly diagnosed malignant glioma in the elderly people: New trials that impact therapy. Int J Clin Pract 2013;67: 1225–1227.
97. Berghoff AS, Stefanits H, Woehrer A et al. Clinical neuropathology practice guide 3-2013: Levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clin Neuropathol 2013;32:148–158.